(Q24245647)

title

Antitumour antibiotic containing regimens for metastatic breast cancer (English)

0 references

main subject

metastatic breast cancer

1 reference

5

0 references

Davina Ghersi

2

0 references

author name string

S Lord

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

D Ghersi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

M Gattellari

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

S Wortley

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

N Wilcken

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

J Simes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

Cochrane Database of Systematic Reviews

14 May 2020

publication date

18 October 2004

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

page(s)

CD003367

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Response and survival in advanced breast cancer after two non-cross-resistant combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Chemotherapy of advanced breast cancer. Results of a controlled trial comparing two three-drug regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

A daily diary for quality of life measurement in advanced breast cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Prognostic Factors in the Initial Response to Therapy by Patients With Advanced Breast Cancer 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Combination chemotherapy of metastatic breast cancer. A randomized trial comparing the use of adriamycin to that of vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma.A southwest cancer chemotherapy study group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003367.PUB2

Combination chemotherapy with cmf (cyclophosphamide, methotrexate, 5-Fluorouracil) versus cnf (mitoxantrone, 5-Fluorouracil, cyclophosphamide) in advanced breast-cancer - a multicenter randomized study.

21 January 2018

1 reference

12 December 2020

Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report

1 reference

12 December 2020

Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy

1 reference

12 December 2020

Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer

1 reference

12 December 2020

Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer

1 reference

12 December 2020

Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel

1 reference

12 December 2020

Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.

1 reference

12 December 2020

A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer

1 reference

12 December 2020

High-intensity therapy versus low-intensity therapy in advanced breast cancer patients

1 reference

12 December 2020

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative

1 reference

12 December 2020

Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study

1 reference

12 December 2020

Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer

1 reference

12 December 2020

A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer

1 reference

12 December 2020

Treatment of metastatic breast cancer: present and future prospects.

1 reference

12 December 2020

Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.

1 reference

12 December 2020

A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study

1 reference

12 December 2020

Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience

1 reference

12 December 2020

Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer

1 reference

12 December 2020

A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study

1 reference

12 December 2020

Refractory breast cancer: a comparison of two different chemotherapy regimens

1 reference

12 December 2020

Rubidazone in metastatic breast cancer

1 reference

12 December 2020

Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and pred

1 reference

12 December 2020

A randomized study comparing oral and standard regimens for metastatic breast cancer.

1 reference

12 December 2020

High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer

1 reference

12 December 2020

Evaluation of a fixed alternating treatment in patients with advanced breast cancer

1 reference

12 December 2020

A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

1 reference

12 December 2020

Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies

1 reference

12 December 2020

Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin

1 reference

12 December 2020

High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast. A phase III study of the Piedmont Oncology Association (POA)

1 reference

12 December 2020

Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy

1 reference

12 December 2020

Current management of advanced breast cancer

1 reference

12 December 2020

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

12 December 2020

A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer

1 reference

12 December 2020

Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association

1 reference

12 December 2020

A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer.

1 reference

12 December 2020

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

12 December 2020

Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results

1 reference

12 December 2020

Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group

1 reference

12 December 2020

An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer

1 reference

12 December 2020

A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer

1 reference

12 December 2020

Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B

1 reference

12 December 2020

Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)

1 reference

12 December 2020

Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial

1 reference

12 December 2020

10.1002/14651858.CD003367.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6999796&resulttype=core&format=json

14 May 2020

PubMed publication ID

15495049

1 reference